267 related articles for article (PubMed ID: 26948096)
1. Expression of insulin-like growth factor II mRNA binding protein 3 (IMP3) in enchondroma and chondrosarcoma.
Shooshtarizadeh T; Nazeri A; Zare-Mirzaie A; Movahedinia S
Pathol Res Pract; 2016 Apr; 212(4):335-9. PubMed ID: 26948096
[TBL] [Abstract][Full Text] [Related]
2. What are the differentiating clinical and MRI-features of enchondromas from low-grade chondrosarcomas?
Douis H; Parry M; Vaiyapuri S; Davies AM
Eur Radiol; 2018 Jan; 28(1):398-409. PubMed ID: 28695356
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of A disintegrin and metalloproteinase 28 is correlated with high histologic grade in conventional chondrosarcoma.
Matsuura S; Oda Y; Matono H; Izumi T; Yamamoto H; Tamiya S; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2010 Mar; 41(3):343-51. PubMed ID: 19896699
[TBL] [Abstract][Full Text] [Related]
4. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors.
Eefting D; Schrage YM; Geirnaerdt MJ; Le Cessie S; Taminiau AH; Bovée JV; Hogendoorn PC;
Am J Surg Pathol; 2009 Jan; 33(1):50-7. PubMed ID: 18852676
[TBL] [Abstract][Full Text] [Related]
5. Minichromosome maintenance protein (MCM6) in low-grade chondrosarcoma: distinction from enchondroma and identification of progressive tumors.
Helfenstein A; Frahm SO; Krams M; Drescher W; Parwaresch R; Hassenpflug J
Am J Clin Pathol; 2004 Dec; 122(6):912-8. PubMed ID: 15539383
[TBL] [Abstract][Full Text] [Related]
6. Use of MicroRNA biomarkers to distinguish enchondroma from low-grade chondrosarcoma.
Zhang L; Yang M; Mayer T; Johnstone B; Les C; Frisch N; Parsons T; Mi QS; Gibson G
Connect Tissue Res; 2017 Mar; 58(2):155-161. PubMed ID: 27267924
[TBL] [Abstract][Full Text] [Related]
7. Enchondroma versus chondrosarcoma in the appendicular skeleton: differentiating features.
Murphey MD; Flemming DJ; Boyea SR; Bojescul JA; Sweet DE; Temple HT
Radiographics; 1998; 18(5):1213-37; quiz 1244-5. PubMed ID: 9747616
[TBL] [Abstract][Full Text] [Related]
8. Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma.
Takeuchi A; Yamamoto Y; Tsuneyama K; Cheng C; Yonekura H; Watanabe T; Shimizu K; Tomita K; Yamamoto H; Tsuchiya H
Cancer; 2007 Jun; 109(12):2532-40. PubMed ID: 17497647
[TBL] [Abstract][Full Text] [Related]
9. D2-40 functions as an effective chondroid marker distinguishing true chondroid tumors from chordoma.
Huse JT; Pasha TL; Zhang PJ
Acta Neuropathol; 2007 Jan; 113(1):87-94. PubMed ID: 17021752
[TBL] [Abstract][Full Text] [Related]
10. Oncofetal protein IMP3: a useful diagnostic biomarker for leiomyosarcoma.
Cornejo K; Shi M; Jiang Z
Hum Pathol; 2012 Oct; 43(10):1567-72. PubMed ID: 22497850
[TBL] [Abstract][Full Text] [Related]
11. PAS inclusions, immunoreactive tenascin and proliferative activity in low-grade chondrosarcomas.
Ranty ML; Michot C; Le Pessot F; Hellot MF; Biga N; Dujardin FH; Simonet J; Billerey C; Metayer J
Pathol Res Pract; 2003; 199(1):29-34. PubMed ID: 12650515
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-inducible factor 1-alpha and vascular endothelial growth factor in cartilage tumors.
Kouvaras E; Christoni Z; Siasios I; Malizos K; Koukoulis GK; Ioannou M
Biotech Histochem; 2019 May; 94(4):283-289. PubMed ID: 30605014
[TBL] [Abstract][Full Text] [Related]
13. Expression of connective tissue growth factor in cartilaginous tumors.
Shakunaga T; Ozaki T; Ohara N; Asaumi K; Doi T; Nishida K; Kawai A; Nakanishi T; Takigawa M; Inoue H
Cancer; 2000 Oct; 89(7):1466-73. PubMed ID: 11013359
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of estrogen receptors in chondrosarcomas and enchondromas.
Grifone TJ; Haupt HM; Podolski V; Brooks JJ
Int J Surg Pathol; 2008 Jan; 16(1):31-7. PubMed ID: 18203781
[TBL] [Abstract][Full Text] [Related]
15. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.
Walter O; Prasad M; Lu S; Quinlan RM; Edmiston KL; Khan A
Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680
[TBL] [Abstract][Full Text] [Related]
16. Dynamic contrast-enhanced MR imaging for differentiation between enchondroma and chondrosarcoma.
De Coninck T; Jans L; Sys G; Huysse W; Verstraeten T; Forsyth R; Poffyn B; Verstraete K
Eur Radiol; 2013 Nov; 23(11):3140-52. PubMed ID: 23771600
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of runx2 and Indian hedgehog in cartilaginous tumors.
Park HR; Park YK
Pathol Oncol Res; 2007; 13(1):32-7. PubMed ID: 17387386
[TBL] [Abstract][Full Text] [Related]
18. Grade 1 chondrosarcoma of bone: a diagnostic and treatment dilemma.
Randall RL; Gowski W
J Natl Compr Canc Netw; 2005 Mar; 3(2):149-56. PubMed ID: 19817027
[TBL] [Abstract][Full Text] [Related]
19. Overutilization and Cost of Advanced Imaging for Long-Bone Cartilaginous Lesions.
Wilson RJ; Zumsteg JW; Hartley KA; Long JH; Mesko NW; Halpern JL; Schwartz HS; Holt GE
Ann Surg Oncol; 2015 Oct; 22(11):3466-73. PubMed ID: 25564171
[TBL] [Abstract][Full Text] [Related]
20. Differential Diagnosis of Cartilaginous Lesions of Bone.
Suster D; Hung YP; Nielsen GP
Arch Pathol Lab Med; 2020 Jan; 144(1):71-82. PubMed ID: 31877083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
